{"groups":[{"description":"Given by one of two regimens. • Mayo Clinic regimen group: LV 20 mg/m\\^2 IV bolus injection + 5-FU 425 mg/m\\^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or • Roswell Park regimen group: LV 500 mg/m\\^2 by two-hour IV infusion + 5-FU 500 mg/m\\^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks)","id":"FG000","title":"5-FU/LV"},{"description":"Capecitabine administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m\\^2 twice-daily (equivalent to a total daily dose of 2000 mg/m\\^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m\\^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks)","id":"FG001","title":"XELOX"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"286"},{"groupId":"FG001","numSubjects":"242"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"20"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"63"},{"groupId":"FG001","numSubjects":"63"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"942"},{"groupId":"FG001","numSubjects":"944"}],"type":"STARTED"},{"achievements":[{"comment":"Safety Population","groupId":"FG000","numSubjects":"926"},{"comment":"Safety Population","groupId":"FG001","numSubjects":"938"}],"type":"Received Treatment"},{"achievements":[{"comment":"total includes Completed and Alive in follow-up","groupId":"FG000","numSubjects":"575"},{"comment":"total includes Completed and Alive in follow-up","groupId":"FG001","numSubjects":"619"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"367"},{"groupId":"FG001","numSubjects":"325"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}